Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.

中文翻译：

---

瑞斯美隆治疗 MASH

Resmetirom 是一种口服选择性 THR-β 激动剂，有条件批准用于治疗伴有中度至晚期纤维化的非肝硬化 MASH 患者。 Resmetirom恢复线粒体和肝脏代谢功能；降低致动脉粥样硬化的脂质；改善肝脏脂肪变性、炎症和纤维化；对THR-α无显着影响。要查看此《Bench to Bedside》，请打开或下载 PDF。